BUY VKTX - VIKING THERAPEUTICS ON A BREAKOUT OF $3.20 USING $2.52 AS A STOP. TRADING TARGETS: $3.50, $4.00, $4.50.

BUY VKTX - VIKING THERAPEUTICS ON A BREAKOUT OF $3.20 USING $2.52 AS A STOP. TRADING TARGETS: $3.20, $3.50, $4.00, $4.50.

 

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder. In addition, it develops VK0612, an orally available drug candidate for the treatment of type 2 diabetes; small molecule agonists of the erythropoietin receptor for the treatment of anemia; and tissue-selective inhibitors of diacylglycerol acyltransferase-1 for the treatment of obesity and dyslipidemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.

By | 2017-12-01T08:29:45+00:00 November 30th, 2017|Trading Addict|0 Comments